Skip to main content
Top

10-10-2023 | Type 2 Diabetes | News

EASD 2023

Real-world study shows reduction in microvascular complications with SGLT2 inhibitors and GLP1 receptor agonists

MedNet.nl: Large cardiovascular outcome studies have shown cardiovascular benefits of SGLT2 inhibitors (SGLT2i) and GLP1 receptor agonists (GLP-1 RA) in people with type 2 diabetes. Both classes of drugs also lower the 5-year risk of microvascular complications, according to a retrospective cohort analysis of 6 million people with type 2 diabetes.

Related topics

A quick guide to ECGs

Electrocardiography Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more